[O-03] Oral Session 03 Neuroimmunology1

[O-03-6] Serum GFAP, but not S100B or neurofilament light chain, predicts future relapses in NMOSD

^○Mitsuru Watanabe¹, David Leppert², Noriko Isobe¹, Takuya Matsushita¹, Aleksandra Maceski², Dimitri Rey², Sandra Mitrovic³, Yuri Nakamurar^1,4,5, Katsuhisa Masaki¹, Jun-ichi Kira^1,4,6, Jens Kuhle² (1.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, 3.Laboratory Medicine, University Hospital Basel, University of Basel, 4.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, 5.School of Pharmacy at Fukuoka, International University of Health and Welfare, 6.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare)